D L Kelly

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, School of Medicine, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 20:71-8. 2008
  2. ncbi Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore School of Medicine, Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 38:543-51. 2012
  3. ncbi Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Box 22147 Baltimore, MD 21228, United States
    Schizophr Res 103:161-8. 2008
  4. ncbi Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychopharmacol 31:86-91. 2011
  5. ncbi Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 15:181-6. 2003
  6. ncbi Atypical antipsychotic use in a state hospital inpatient adolescent population
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, USA
    J Child Adolesc Psychopharmacol 14:75-85. 2004
  7. ncbi Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD 21228, USA
    J Psychiatr Res 38:531-6. 2004
  8. ncbi Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine
    Deanna L Kelly
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychiatry 66:80-4. 2005
  9. ncbi First-episode schizophrenia: a focus on pharmacological treatment and safety considerations
    Deanna L Kelly
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21228, USA
    Drugs 65:1113-38. 2005
  10. ncbi Reaching for wellness in schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychiatr Clin North Am 30:453-79. 2007

Research Grants

  1. Cardiac-Related Mortality with Atypical Antipsychotics
    DEANNA KELLY; Fiscal Year: 2005
  2. Comorbid Substance Abuse and Long-Term Health Outcomes in Schizophrenia
    DEANNA KELLY; Fiscal Year: 2007

Detail Information

Publications61

  1. ncbi Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, School of Medicine, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 20:71-8. 2008
    ..This study examined weight and metabolic changes with two widely used antipsychotics, risperidone and olanzapine; addressing the issue of early monitoring for metabolic side effects...
  2. ncbi Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore School of Medicine, Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 38:543-51. 2012
    ....
  3. ncbi Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Box 22147 Baltimore, MD 21228, United States
    Schizophr Res 103:161-8. 2008
    ..53, df=1, p=0.019), for an effect size of 0.4. These results suggest that galantamine has no effect on cigarette smoking and that during galantamine treatment nicotine dependency scores worsen...
  4. ncbi Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychopharmacol 31:86-91. 2011
    ..The endocannabinoid system remains a promising target for pharmacotherapy of schizophrenia and obesity...
  5. ncbi Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 15:181-6. 2003
    ..High doses of olanzapine during 8 weeks of treatment did not increase lipids and liver enzymes like clozapine did. Olanzapine at 50 mg/day may be associated with more anticholinergic effects and weight gain than clozapine...
  6. ncbi Atypical antipsychotic use in a state hospital inpatient adolescent population
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, USA
    J Child Adolesc Psychopharmacol 14:75-85. 2004
    ..More research is needed to develop useful and specific practice guidelines in children and adolescents for these commonly used medications...
  7. ncbi Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD 21228, USA
    J Psychiatr Res 38:531-6. 2004
    ..Individuals who die by suicide experience higher rates of depressive symptoms, suicidal thoughts and positive symptoms during their life...
  8. ncbi Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine
    Deanna L Kelly
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychiatry 66:80-4. 2005
    ..Furthermore, the need for thyroid function monitoring in patients taking this medication is not definitive...
  9. ncbi First-episode schizophrenia: a focus on pharmacological treatment and safety considerations
    Deanna L Kelly
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21228, USA
    Drugs 65:1113-38. 2005
    ....
  10. ncbi Reaching for wellness in schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychiatr Clin North Am 30:453-79. 2007
    ..Although treatment of risk factors for CHD is still far from ideal, all attempts should be made to strive for wellness to improve patients' long-term outcomes...
  11. ncbi Sexuality and schizophrenia: a review
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 30:767-79. 2004
    ..Treatment options and psychosocial issues pertaining to sexuality also are presented...
  12. ncbi Treatment considerations in women with schizophrenia
    Deanna L Kelly
    Department of Psychiatry, School of Medicine, Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    J Womens Health (Larchmt) 15:1132-40. 2006
    ..Additionally, it presents patient counseling issues in sexuality and health outcomes...
  13. ncbi Clozapine underutilization and discontinuation in African Americans due to leucopenia
    Deanna L Kelly
    The Maryland Psychiatric Research Center, Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 33:1221-4. 2007
    ....
  14. ncbi Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Box 21247, Baltimore, MD 21228, USA
    Psychiatr Q 77:81-95. 2006
    ..The addition of divalproex was significantly more effective in reducing global symptoms (driven by hostility and anxiety) in the first month of adjunct treatment as compared to clozapine monotherapy and to previous clozapine treatment...
  15. ncbi Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study
    D L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD, USA
    J Psychopharmacol 23:436-41. 2009
    ..Future studies should aim to relate remission criteria to functional outcomes, cognition, and other important symptom domains...
  16. ncbi Clozapine utilization and outcomes by race in a public mental health system: 1994-2000
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore 21228, USA
    J Clin Psychiatry 67:1404-11. 2006
    ..This study extends previous studies of clozapine by examining patient- and treatment-related factors that may help explain or eliminate reasons for differential prescribing...
  17. ncbi Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine
    D L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychiatr Serv 52:676-8. 2001
    ..These data suggest that among inpatients with schizophrenia or schizoaffective disorder, use of risperidone results in a higher discharge rate and a lower drug cost than use of olanzapine...
  18. ncbi The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disorders
    D L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 21228, USA
    Osteoporos Int 22:1133-43. 2011
    ..Prevalence of osteoporosis was increased compared to controls in women with major mood disorders or women over 55 dually diagnosed with psychosis and substance use disorder...
  19. ncbi Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations
    D L Kelly
    University of Maryland School of Medicine, Maryland Psychiatric Research Center, Box 21247, Baltimore, MD 21228, USA
    Psychopharmacol Bull 35:66-79. 2001
    ..This paper will review the literature concerning real and theoretical implications of pharmacokinetic and pharmacodynamic interactions with ziprasidone, particularly with regard to these effects on the QTc interval...
  20. ncbi Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, P O Box 21247, Baltimore, MD 21228, USA
    Compr Psychiatry 51:298-302. 2010
    ....
  21. ncbi A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Box 21247, Baltimore, 21228, USA
    Psychoneuroendocrinology 31:340-6. 2006
    ..Overall, quetiapine was associated with a normalization of prolactin levels and had the greatest benefits among these drugs regarding sexual functioning...
  22. ncbi Clozapine treatment in patients with prior substance abuse
    Deanna L Kelly
    School of Medicine, University of Maryland, Baltimore, Maryland, USA
    Can J Psychiatry 48:111-4. 2003
    ..This study examined outcomes following discharge on clozapine for treatment-resistant schizophrenia patients with and without diagnosed substance abuse histories...
  23. ncbi Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Box 21247, Baltimore, MD 21228, USA
    J Clin Psychiatry 71:304-11. 2010
    ..Cardiovascular disease (CVD) mortality in schizophrenia is more frequent than in the general population. Whether second-generation antipsychotics (SGAs) increase risk of CVD morbidity and mortality has yet to be determined...
  24. ncbi Cigarette smoking and mortality risk in people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Schizophr Bull 37:832-8. 2011
    ..Greater smoking severity significantly increases this risk. Smoking cessation in people with schizophrenia deserves significant attention...
  25. ncbi A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychiatry 70:518-25. 2009
    ..In animals, it has been shown to increase extracellular levels of acetylcholine and dopamine in cortical and hippocampal regions...
  26. ncbi Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, United States
    Schizophr Res 107:134-8. 2009
    ....
  27. ncbi Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, Treatment Research Unit, University of Maryland, Baltimore 21228, USA
    Clin Neuropharmacol 28:163-8. 2005
    ..Treatment with first- and second-generation antipsychotics may demonstrate similar efficacy; however, patients treated with second-generation antipsychotics may be more likely to adhere to treatment...
  28. ncbi Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse
    R R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, School of Medicine 21228, USA
    Schizophr Res 33:95-101. 1998
    ..This suggests that olanzapine may be of benefit to SA patients who have a greater tendency for antipsychotic side effects and tardive dyskinesia...
  29. ncbi The effects of galantamine on psychopathology in chronic stable schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Clin Neuropharmacol 32:69-74. 2009
    ..This secondary analysis describes the effects of galantamine on psychopathology in people with schizophrenia...
  30. ncbi Plasma concentrations of high-dose olanzapine in a double-blind crossover study
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Hum Psychopharmacol 21:393-8. 2006
    ..In conclusion, this study reports plasma olanzapine levels at high fixed doses of olanzapine (50 mg/day) in relation to side effects, symptoms, smoking, and gender...
  31. ncbi Management of treatment resistance in schizophrenia
    R R Conley
    Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228, USA
    Biol Psychiatry 50:898-911. 2001
    ....
  32. ncbi Cardiovascular disease in relation to weight in deceased persons with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, 21228, USA
    Compr Psychiatry 46:460-7. 2005
    ....
  33. ncbi The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD 21228, USA
    J Psychopharmacol 18:429-31. 2004
    ..These findings suggest that high doses of olanzapine do not produce similar brain activation patterns as clozapine in people with treatment-resistant schizophrenia...
  34. ncbi Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research
    Robert P McMahon
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland Baltimore Medical School, Baltimore, MD, USA
    Schizophr Bull 34:292-301. 2008
    ..Shortening placebo-controlled trials would reduce patient burden and ethical objections to prolonged administration of placebo and reduce potential bias due to high dropout rates in longer clinical trials...
  35. ncbi Comparison of clozapine response for inpatients in the research setting versus routine clinical practice
    Douglas L Boggs
    Maryland Psychiatric Research Center, School of Medicine, University of Maryland Baltimore, Baltimore, MD 21228, USA
    Psychiatr Q 79:111-9. 2008
    ..This study compares patient characteristics and treatment response between inpatients treated with clozapine in a research setting as compared to those initiated on clozapine during routine inpatient treatment...
  36. ncbi Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients
    Robert R Conley
    Maryland Psychiatric Research Center in the University of Maryland School of Medicine at Baltimore, MD 21228, USA
    Psychopharmacol Bull 40:77-97. 2007
    ..This review will assess the clinical relevance of these interactions for physicians and patients with schizophrenia...
  37. ncbi Comparison of clozapine use in Maryland and in Victoria, Australia
    Robert R Conley
    Maryland Psyciatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Psychiatr Serv 56:320-3. 2005
    ..This study examined the use of clozapine in Maryland and in Victoria, Australia...
  38. ncbi Rehospitalization risk with second-generation and depot antipsychotics
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 15:23-31. 2003
    ..SGAs may provide better long-term prognoses and outcomes for patients with schizophrenia...
  39. ncbi Current status of antipsychotic treatment
    Robert R Conley
    University of Maryland, Maryland Psychiatric Research Center, Baltimore, MD 21228, USA
    Curr Drug Targets CNS Neurol Disord 1:123-8. 2002
    ..Optimization of treatment and understanding the exact mechanism of action of current antipsychotic medications will help pave the way for new drug targets in the future...
  40. ncbi Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone
    Matthew W Nelson
    VA Capitol Healthcare Network Mental Illness Research Education and Clinical Care Center MIRECC, Veterans Affairs, Maryland Health Care System, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Clin Neuropharmacol 26:297-8. 2003
    ..Controlled trials of quetiapine in the treatment of tardive dyskinesia should be pursued...
  41. ncbi Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials
    Robert P McMahon
    Department of Psychiatry, Maryland Psychiatric Research Center, Spring Grove Hospital Grounds, Maple and Locust Avenues, PO Box 21247, Baltimore, MD 21228, USA
    Neuropsychopharmacology 26:537-45. 2002
    ..We recommend these four factor scores as clinical trial outcomes in patients with treatment resistant schizophrenia...
  42. ncbi The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 36:71-93. 2010
    ....
  43. ncbi Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients
    J D Sherr
    School of Pharmacy, University of Maryland, Baltimore, USA
    Psychiatr Serv 49:1355-7. 1998
    ..Costs were reduced 83 percent; annual savings per patient was approximately $905. These preliminary results suggest that many chronic psychiatric inpatients stabilized on divalproex may be safely switched to valproic acid...
  44. ncbi Circumstances of suicide among individuals with schizophrenia
    Julie A Kreyenbuhl
    Maryland Psychiatric Research Center, University of Maryland, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Res 58:253-61. 2002
    ..Suicide in schizophrenia is a significant clinical problem; thus, prior suicidal activity and depressive symptoms should be addressed because opportunities to intervene immediately before the act are limited...
  45. ncbi Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland, USA
    Isr J Psychiatry Relat Sci 42:51-60. 2005
    ..Because certain side effects may be associated with nonadherence with treatment, more detailed data for each of the SGA with regards to EPS, weight gain and metabolic abnormalities and sexual dysfunction are presented...
  46. ncbi Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers
    Kenneth H Levin
    Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD 21224, USA
    Drug Alcohol Depend 111:120-7. 2010
    ..Cannabis withdrawal is not recognized in DSM-IV because of doubts about its clinical significance...
  47. ncbi Evaluating sexual function in patients with treatment-resistant schizophrenia
    Deanna L Kelly
    Schizophr Res 63:195-6. 2003
  48. ncbi Olanzapine and risperidone
    Raymond C Love
    Am J Health Syst Pharm 60:487-8; author reply 488-9. 2003
  49. ncbi Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study
    Do-Un Jung
    Department of Psychiatry, Dongseo Hospital, Masan, Republic of Korea
    J Clin Psychiatry 67:1391-6. 2006
    ..CONCLUSIONS: Bone mineral density loss in patients with schizophrenia tended to differ by gender. Decreased BMD compared to normal controls was seen in female patients; however, this was not observed in men...
  50. ncbi Fluoxetine augmentation of haloperidol in chronic schizophrenia
    Joo-Cheol Shim
    J Clin Psychopharmacol 23:520-2. 2003
  51. ncbi The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study
    Robert R Conley
    J Clin Psychopharmacol 23:668-71. 2003
  52. ncbi Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine
    Deanna L Kelly
    J Clin Psychiatry 64:1133-4. 2003
  53. ncbi The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia
    Do-Un Jung
    J Clin Psychopharmacol 25:613-5. 2005
  54. ncbi Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis
    Joo Cheol Shim
    J Clin Psychopharmacol 27:400-1. 2007
  55. ncbi Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia
    Joo-Cheol Shim
    Department of Psychiatry, Inje University, Busan, Korea
    J Neuropsychiatry Clin Neurosci 17:221-6. 2005
    ..This finding suggests that decreased dopamine (D(2)) receptor sensitivity may result in lower risk of developing TD and may lead to a fuller understanding of the variable expression of D(2)-receptor mediated side effects...
  56. ncbi Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial
    Joo Cheol Shim
    Clinical Trial Center, Department of Psychiatry and Clinical Pharmacology, Busan Paik Hospital, Inje University, Busan 614 735, Republic of Korea
    Am J Psychiatry 164:1404-10. 2007
    ..The authors investigated the effect of adjunctive treatment with aripiprazole on hyperprolactinemia and psychopathology in patients with schizophrenia maintained with haloperidol...
  57. ncbi Quetiapine at high doses for the treatment of refractory schizophrenia
    Douglas L Boggs
    Schizophr Res 101:347-8. 2008
  58. ncbi Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis
    Tim Lambert
    J Clin Psychopharmacol 24:91-3. 2004
  59. ncbi Deaths from diabetic ketoacidosis after long-term clozapine treatment
    Heidi J Wehring
    Am J Psychiatry 160:2241-2. 2003
  60. ncbi Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report
    Joo-Cheol Shim
    J Clin Psychopharmacol 28:353-4. 2008
  61. ncbi Cortisol response to buspirone in extended abstinent alcoholics
    Young-Hoon Kim
    Department of Psychiatry, Busan Paik Hospital 633-165 Gaegum-Dong, Busanjin-Gu, 614-735, Republic of Korea
    Alcohol Alcohol 39:287-9. 2004
    ..Our results show that cortisol response to buspirone was significantly decreased in alcoholic patients compared to normal controls, reflecting decreased 5-HT1A receptor sensitivity...

Research Grants3

  1. Cardiac-Related Mortality with Atypical Antipsychotics
    DEANNA KELLY; Fiscal Year: 2005
    ..This study is important as data on long-term health outcomes with atypical antipsychotics is lacking from the literature. ..
  2. Comorbid Substance Abuse and Long-Term Health Outcomes in Schizophrenia
    DEANNA KELLY; Fiscal Year: 2007
    ..This will be an important step for improving the lives of people with schizophrenia. ..